MTOR and neoplasm: By combining everolimus with panobinostat we elude possible tumor escape mechanisms in response to mTOR inhibition (increased AR transcriptional activity and expression of known onco-miRs), resulting in, at least with this combination, cytostatic anti-tumor activity.